Panchal Preyash A, Patel Shruti, Patel Asha, Ahlawat Priyanka
Department of Pharmaceutics, Parul Institute of Pharmacy, Parul University, Vadodara, Gujarat, 391760, India.
Pharm Nanotechnol. 2024;12(5):428-437. doi: 10.2174/2211738511666230912160729.
The common symptom of systemic atherosclerosis is peripheral arterial disease (PAD), which occurs when the artery lumen in the lower extremities gradually becomes blocked by atherosclerotic plaque. The most frequent symptom of lower extremity PAD, called "vascular claudication," which is pain experienced when walking. Partial or total blockage of the peripheral arteries in the upper and lower limbs is called PAD. The danger of death from concurrent coronary artery and cerebrovascular atherosclerosis outweighs the risk of amputation.
However, niosomes have issues with fusion, aggregation, leakage, vesicle sedimentation, and difficulty in sterilizing. A more recent strategy known as pro-vesicular carriers was used to solve these issues. The formulations in Proniosomes are dry and anhydrous, protected with a non-ionic surfactant that serves as a carrier when combined with water.
Formulation prepared by organic solvent, surfactant, cholesterol, other components and hydration medium. Coacervation Phase separation Technique used for proniosome Nanoparticle. Box Bhenken Design is used for optimization batches.
In this context, we shall discuss the development of Proniosome for the treatment of peripheral arterial diseases. From here, we know that proniosome nanoparticles is pro vesicular system good characteristics and effectiveness for treating peripheral arterial diseases.
Proniosomes may be created using various techniques, which may impact how they develop along with the drug's characteristics. They increase the drug's stability while being delivered while being entrapped. They don't need particular conditions for handling, protection, storage, or industrial manufacturing.
系统性动脉粥样硬化的常见症状是外周动脉疾病（PAD），当下肢动脉管腔逐渐被动脉粥样硬化斑块阻塞时就会发生。下肢PAD最常见的症状称为“血管性间歇性跛行”，即行走时出现的疼痛。上肢和下肢外周动脉的部分或完全阻塞称为PAD。冠状动脉和脑血管动脉粥样硬化并发导致的死亡风险超过截肢风险。
然而，脂质体存在融合、聚集、渗漏、囊泡沉降以及灭菌困难等问题。一种称为前体囊泡载体的最新策略被用于解决这些问题。前体脂质体中的制剂是干燥无水的，用非离子表面活性剂保护，当与水混合时该表面活性剂作为载体。
由有机溶剂、表面活性剂、胆固醇、其他成分和水合介质制备制剂。采用凝聚相分离技术制备前体脂质体纳米颗粒。使用Box - Behnken设计优化批次。
在这种情况下，我们将讨论用于治疗外周动脉疾病的前体脂质体的开发。由此我们知道，前体脂质体纳米颗粒是一种前体囊泡系统，在治疗外周动脉疾病方面具有良好的特性和有效性。
前体脂质体可以使用各种技术制备，这可能会影响它们的发展以及药物的特性。它们在包裹药物递送时提高了药物的稳定性。它们在处理、保护、储存或工业生产方面不需要特殊条件。
